Resistance to antiretroviral drugs in patients with primary HIV-1 infection

International Journal of Antimicrobial Agents

Volumn 16, Issue 4, 2000, Pages 429-434

  Brenner, Bluma ^a   Wainberg, Mark A ^a   Salomon, Horacio ^a   Rouleau, Danielle ^b   Dascal, André ^a   Spira, Bonnie ^a   Sekaly, Rafik Pierre ^c   Conway, Brian ^d   Routy, Jean Pierre ^e  

^a MCGILL UNIVERSITY   (Canada)

^b Fonds de la Recherche en Sante du Quebec   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d Viridae Clinical Sciences Inc   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Antiretroviral therapy; HIV drug resistance resistance mutations; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0033673684     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00270-3     Document Type: Article

References (27)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Public health implications of antiretroviral therapy and HIV drug resistance
3. Antiretroviral drug resistance testing in adults with HIV infection
4. Mutations in retroviral genes associated in drug resistance
5. Virologic and clinical implications of resistance to HIV-1 protease inhibitors
6. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
7. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
8. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment
9. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
10. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
11. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
12. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
13. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors
14. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts
15. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group
16. Transmission of multidrug-resistant human immunodeficiency virus - The wakeup call
17. Mutations associated with zidovudine resistance in HIV-1 among recent seroconverters
18. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands
19. Prevalence of AZT-Resistant (AZT(R)) HIV-1 Persons Seroconverting in Switzerland, Australia, and the United States Between 1988 and 1994
20. Transmission of antiretroviral-drug-resistant HIV-1 variants
21. HIV-1 drug resistance in newly infected individuals
22. Reduced antiretroviral drug susceptibility among patients with primary infection
23. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1
24. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells
25. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine
26. Is HIV resistance to 3TC of clinical benefit?
27. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme